Ligand id: 6780

Name: rituximab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: rituximab

Immunopharmacology Comments
Rituximab is the first biological agent to show positive effects on biological and clinical disease parameters in Sjögren's syndrome [1,7].
Immunopharmacology Disease
Disease X-Refs Comment References
Chronic lymphocytic leukemia Disease Ontology: DOID:1040
OMIM: 151400
Orphanet: ORPHA67038
An anti-CD20 therapy approved for CLL and non-Hodgkins lymphoma.
Rheumatoid arthritis Disease Ontology: DOID:7148
OMIM: 180300
An anti-CD20 therapy approved for RA.
Pemphigus Disease Ontology: DOID:9182
Rituximab is the first biologic therapy approved for pemphigus vulgaris (PV), and represents the first major PV therapeutic advance in more than 60 years.
Immunopaedia Case Studies Links
My eyes cross at twilight
A 7 year old with severe muscle weakness and difficulty walking
A case of lymphadenopathy and night sweats
My head hurts and I cannot speak?